» Articles » PMID: 30871006

The Impact of the C-Terminal Region on the Interaction of Topoisomerase II Alpha with Mitotic Chromatin

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Mar 16
PMID 30871006
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Type II topoisomerase enzymes are essential for resolving DNA topology problems arising through various aspects of DNA metabolism. In vertebrates two isoforms are present, one of which (TOP2A) accumulates on chromatin during mitosis. Moreover, TOP2A targets the mitotic centromere during prophase, persisting there until anaphase onset. It is the catalytically-dispensable C-terminal domain of TOP2 that is crucial in determining this isoform-specific behaviour. In this study we show that, in addition to the recently identified chromatin tether domain, several other features of the alpha-C-Terminal Domain (CTD). influence the mitotic localisation of TOP2A. Lysine 1240 is a major SUMOylation target in cycling human cells and the efficiency of this modification appears to be influenced by T1244 and S1247 phosphorylation. Replacement of K1240 by arginine results in fewer cells displaying centromeric TOP2A accumulation during prometaphase-metaphase. The same phenotype is displayed by cells expressing TOP2A in which either of the mitotic phosphorylation sites S1213 or S1247 has been substituted by alanine. Conversely, constitutive modification of TOP2A by fusion to SUMO2 exerts the opposite effect. FRAP analysis of protein mobility indicates that post-translational modification of TOP2A can influence the enzyme's residence time on mitotic chromatin, as well as its subcellular localisation.

Citing Articles

Human Topoisomerase IIα Promotes Chromatin Condensation Via a Phase Transition.

Wu M, Beck C, Lee J, Fulbright Jr R, Jeong J, Inman J bioRxiv. 2024; .

PMID: 39464128 PMC: 11507700. DOI: 10.1101/2024.10.15.618281.


Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications.

Soliman T, Keifenheim D, Parker P, Clarke D J Cell Biol. 2023; 222(12).

PMID: 37955972 PMC: 10641588. DOI: 10.1083/jcb.202209125.


Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity.

Salem M, Abu El-Ata S, Elsayed E, Mali S, Alshwyeh H, Almaimani G RSC Adv. 2023; 13(47):33080-33095.

PMID: 37954422 PMC: 10633821. DOI: 10.1039/d3ra06189b.


miR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A.

Huang X, Jia Y, Shi H, Fan H, Sun L, Zhang H Asian Biomed (Res Rev News). 2023; 17(3):124-135.

PMID: 37818158 PMC: 10561683. DOI: 10.2478/abm-2023-0052.


Telling Your Right Hand from Your Left: The Effects of DNA Supercoil Handedness on the Actions of Type II Topoisomerases.

Jian J, Osheroff N Int J Mol Sci. 2023; 24(13).

PMID: 37446377 PMC: 10342825. DOI: 10.3390/ijms241311199.


References
1.
Mirski S, Gerlach J, Cole S . Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II. Exp Cell Res. 1999; 251(2):329-39. DOI: 10.1006/excr.1999.4587. View

2.
Mao Y, Desai S, Liu L . SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem. 2000; 275(34):26066-73. DOI: 10.1074/jbc.M001831200. View

3.
Waizenegger I, Hauf S, Meinke A, Peters J . Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase. Cell. 2000; 103(3):399-410. DOI: 10.1016/s0092-8674(00)00132-x. View

4.
Zeitlin S, Barber C, Allis C, Sullivan K, Sullivan K . Differential regulation of CENP-A and histone H3 phosphorylation in G2/M. J Cell Sci. 2001; 114(Pt 4):653-61. DOI: 10.1242/jcs.114.4.653. View

5.
Tatham M, Jaffray E, Vaughan O, Desterro J, Botting C, Naismith J . Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem. 2001; 276(38):35368-74. DOI: 10.1074/jbc.M104214200. View